A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Titel:
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Auteur:
Loibl, S. Untch, M. Burchardi, N. Huober, J. Sinn, B.V. Blohmer, J.-U. Grischke, E.-M. Furlanetto, J. Tesch, H. Hanusch, C. Engels, K. Rezai, M. Jackisch, C. Schmitt, W.D. von Minckwitz, G. Thomalla, J. Kümmel, S. Rautenberg, B. Fasching, P.A. Weber, K. Rhiem, K. Denkert, C. Schneeweiss, A.